CapsoVision, Inc. Common Stock
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. It offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps… Read more
CapsoVision, Inc. Common Stock (CV) - Net Assets
Latest net assets as of September 2025: $20.44 Million USD
Based on the latest financial reports, CapsoVision, Inc. Common Stock (CV) has net assets worth $20.44 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($25.66 Million) and total liabilities ($5.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $20.44 Million |
| % of Total Assets | 79.66% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CapsoVision, Inc. Common Stock - Net Assets Trend (2023–2024)
This chart illustrates how CapsoVision, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CapsoVision, Inc. Common Stock (2023–2024)
The table below shows the annual net assets of CapsoVision, Inc. Common Stock from 2023 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-129.51 Million | -17.90% |
| 2023-12-31 | $-109.84 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CapsoVision, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1989800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | % |
| Other Components | $838.00K | % |
| Total Equity | $-129.51 Million | 100.00% |
CapsoVision, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of CapsoVision, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Safilo Group S.p.A
PINK:SAFLF
|
$158.17 Million |
|
Kcc Glass Corp
KO:344820
|
$158.22 Million |
|
Zhejiang Yiming Food Co. Ltd.
SHG:605179
|
$158.26 Million |
|
Trusval Technology Co Ltd
TWO:6667
|
$158.26 Million |
|
ECKOH PLC LS-0025
F:TZ5A
|
$158.10 Million |
|
Serko Limited
PINK:SERKF
|
$158.03 Million |
|
Hangzhou Landscaping Incorporated
SHG:605303
|
$157.95 Million |
|
TortoiseEcofin Acquisition Corp. III
PINK:TRTLF
|
$157.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CapsoVision, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -109,843,000 to -129,510,000, a change of -19,667,000.
- Net loss of 19,898,000 reduced equity.
- New share issuances of 15,000,000 increased equity.
- Other factors decreased equity by 14,769,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.90 Million | -15.36% |
| Share Issuances | $15.00 Million | +11.58% |
| Other Changes | $-14.77 Million | -11.4% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares CapsoVision, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $-2.37 | $5.52 | x |
| 2024-12-31 | $-3.35 | $5.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CapsoVision, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -169.26%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | 0.00% | -115.91% | 0.45x | 0.00x | $-320.70K |
| 2024 | 0.00% | -169.26% | 0.70x | 0.00x | $-6.95 Million |
Industry Comparison
This section compares CapsoVision, Inc. Common Stock's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CapsoVision, Inc. Common Stock (CV) | $20.44 Million | 0.00% | 0.26x | $158.13 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |